相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice
Neele Schumacher et al.
JOURNAL OF HEPATOLOGY (2021)
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future
Geert R. D'Haens et al.
GUT (2021)
Transneuronal delivery of hyper-interleukin-6 enables functional recovery after severe spinal cord injury in mice
Marco Leibinger et al.
NATURE COMMUNICATIONS (2021)
ADAM17 Deficiency Protects against Pulmonary Emphysema
Mohamed Saad et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2021)
Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease
Stefan Schreiber et al.
GASTROENTEROLOGY (2021)
The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design
Robert A. Saxton et al.
IMMUNITY (2021)
A myeloid-stromal niche and gp130 rescue in NOD2-driven Crohn's disease
Shikha Nayar et al.
NATURE (2021)
Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10
Robert A. Saxton et al.
SCIENCE (2021)
Selective Interleukin-6 Trans-Signaling Blockade Is More Effective Than Panantagonism in Reperfused Myocardial Infarction
Marc Jonathan George et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2021)
Repopulating Microglia Promote Brain Repair in an IL-6-Dependent Manner
Emily F. Willis et al.
CELL (2020)
Biological functions and therapeutic opportunities of soluble cytokine receptors
Juliane Lokau et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2020)
Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease (vol 180, pg 79, 2020)
June-Yong Lee et al.
CELL (2020)
Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro
Charlotte M. Flynn et al.
SCIENTIFIC REPORTS (2020)
ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer
Mohamed I. Saad et al.
EMBO MOLECULAR MEDICINE (2019)
Hepatocytes direct the formation of a pro-metastatic niche in the liver
Jae W. Lee et al.
NATURE (2019)
The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes
Samadhi Aparicio-Siegmund et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2019)
Targeting immune cell circuits and trafficking in inflammatory bowel disease
Markus F. Neurath
NATURE IMMUNOLOGY (2019)
ADAM17: An Emerging Therapeutic Target for Lung Cancer
Mohamed Saad et al.
CANCERS (2019)
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer
Neele Schumacher et al.
CANCERS (2019)
De novo design of potent and selective mimics of IL-2 and IL-15
Daniel-Adriano Silva et al.
NATURE (2019)
Interleukin-6 Receptor Signaling and Abdominal Aortic Aneurysm Growth Rates
Ellie Paige et al.
CIRCULATION-GENOMIC AND PRECISION MEDICINE (2019)
Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma
Anna K. Scherger et al.
JCI INSIGHT (2019)
Interleukin-6 Family Cytokines
Stefan Rose-John
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Distinct Effects of IL-6 Classic and Trans-Signaling in Bone Fracture Healing
Katja Prystaz et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
A New Venue of TNF Targeting
Sophie Steeland et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling
Stefanie Schmidt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Interleukin-6: designing specific therapeutics for a complex cytokine
Christoph Garbers et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma
Kathrin Kaiser et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2018)
Biopharmaceutical benchmarks 2018
Gary Walsh
NATURE BIOTECHNOLOGY (2018)
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Simon A. Jones et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
IL-6 Trans-Signaling Is Essential for the Development of Hepatocellular Carcinoma in Mice
Juri Bergmann et al.
HEPATOLOGY (2017)
Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
Sylvia Heink et al.
NATURE IMMUNOLOGY (2017)
Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation
Steffen Riethmueller et al.
PLOS BIOLOGY (2017)
Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling
Philipp Arnold et al.
SCIENTIFIC REPORTS (2017)
Quantitative proteomics screen identifies a substrate repertoire of rhomboid protease RHBDL2 in human cells and implicates it in epithelial homeostasis
Nicholas Johnson et al.
SCIENTIFIC REPORTS (2017)
IL-6 Trans-Signaling Drives Murine Crescentic GN
Gerald S. Braun et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
George D. Kalliolias et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Daniella M. Schwartz et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Therapeutic Targeting of the IL-6 Trans-Signaling/Mechanistic Target of Rapamycin Complex 1 Axis in Pulmonary Emphysema
Saleela M. Ruwanpura et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis
Gavin D. Brooks et al.
CANCER RESEARCH (2016)
Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling
Janina Wolf et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Harnessing the natural inhibitory domain to control TNFα Converting Enzyme (TACE) activity in vivo
Eitan Wong et al.
SCIENTIFIC REPORTS (2016)
Proteolytic Cleavage Governs Interleukin-11 Trans-signaling
Juliane Lokau et al.
CELL REPORTS (2016)
Insights into Cytokine-Receptor Interactions from Cytokine Engineering
Jamie B. Spangler et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
The soluble interleukin-6 receptor and related proteins
Stefan Rose-John
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Interleukin-6: Biology, signaling and strategies of blockade
Fred Schaper et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps
Suman Mitra et al.
IMMUNITY (2015)
Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer
Freya A. Goumas et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Inflammation-Induced IL-6 Functions as a Natural Brake on Macrophages and Limits GN
Michael Luig et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
IL-6 as a keystone cytokine in health and disease
Christopher A. Hunter et al.
NATURE IMMUNOLOGY (2015)
Demyelination and other neurological adverse events after anti-TNF therapy
Evripidis Kaltsonoudis et al.
AUTOIMMUNITY REVIEWS (2014)
IL-6 trans-Signaling-Dependent Rapid Development of Cytotoxic CD8+ T Cell Function
Jan P. Boettcher et al.
CELL REPORTS (2014)
IL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 Signaling
Judith Hoge et al.
JOURNAL OF IMMUNOLOGY (2013)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases
Ricardo C. Ferreira et al.
PLOS GENETICS (2013)
Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice
Harald Schuett et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Hitting a complex target: an update on interleukin-6 trans-signalling
Georg H. Waetzig et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis
Jan Sodenkamp et al.
IMMUNOBIOLOGY (2012)
IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
Stefan Rose-John
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
The interleukin 6 pathway and atherosclerosis
Juergen Scheller et al.
LANCET (2012)
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
Nadeem Sarwar et al.
LANCET (2012)
Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
Marina Lesina et al.
CANCER CELL (2011)
Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model
Tanja Barkhausen et al.
CRITICAL CARE MEDICINE (2011)
Species Specificity of ADAM10 and ADAM17 Proteins in Interleukin-6 (IL-6) Trans-signaling and Novel Role of ADAM10 in Inducible IL-6 Receptor Shedding
Christoph Garbers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Simon A. Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
IL-6 Trans-Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3
Claire J. Greenhill et al.
JOURNAL OF IMMUNOLOGY (2011)
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice
Athena Chalaris et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Structural Biology of Shared Cytokine Receptors
Xinquan Wang et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
Sergei Grivennikov et al.
CANCER CELL (2009)
Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis
Mari A. Nowell et al.
JOURNAL OF IMMUNOLOGY (2009)
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
Sandra Rebouissou et al.
NATURE (2009)
Transgenic blockade of interleukin 6 transsignaling abrogates inflammation
Bjorn Rabe et al.
BLOOD (2008)
Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils
Athena Chalaris et al.
BLOOD (2007)
Cutting edge:: Trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+ CD25- T cells
Sabine Dominitzki et al.
JOURNAL OF IMMUNOLOGY (2007)
Multistep carcinogenesis of the colon in Apc(Min/+) mouse
Yasuhiro Yamada et al.
CANCER SCIENCE (2007)
STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice
K. Mitsuyama et al.
GUT (2006)
Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells
Christiane Stuhlmann-Laeisz et al.
MOLECULAR BIOLOGY OF THE CELL (2006)
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
E Bettelli et al.
NATURE (2006)
Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis
Peter J. Richards et al.
ARTHRITIS AND RHEUMATISM (2006)
TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells
M Veldhoen et al.
IMMUNITY (2006)
Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors
XQ Wang et al.
SCIENCE (2005)
Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
SR Dillon et al.
NATURE IMMUNOLOGY (2004)
TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling
C Becker et al.
IMMUNITY (2004)
Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE)
V Matthews et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: Blockade of arthritis severity by soluble glycoprotein 130
MA Nowell et al.
JOURNAL OF IMMUNOLOGY (2003)
Cytokines as therapeutic drugs
H Schooltink et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2002)
Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6
S Viswanathan et al.
STEM CELLS (2002)
IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation
SM Hurst et al.
IMMUNITY (2001)
Hyper-IL-6 gene therapy reverses fulminant hepatic failure
N Hecht et al.
MOLECULAR THERAPY (2001)
Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells
J Audet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses
T Jostock et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration
M Peters et al.
GASTROENTEROLOGY (2000)
Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury
E Galun et al.
FASEB JOURNAL (2000)
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:: Evidence in Crohn disease and experimental colitis in vivo
R Atreya et al.
NATURE MEDICINE (2000)
分享论文
